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Abstract 
Background: A recent large UK clinical trial demonstrated that positron-emission 
tomography–computed tomography (PET-CT)- guided administration of neck dissection in 
patients with advanced head and neck cancer after primary chemo-radiotherapy treatment 
produces similar survival outcomes to planned neck dissection (standard care) and is cost-
effective over a short-term horizon. Further assessment of long-term outcomes is required in 
order to inform a robust adoption decision.  Here we present results of a lifetime cost-
effectiveness analysis of PET-CT guided management from a UK secondary care perspective. 
Methods: Initial 6-month cost and health outcomes were derived from trial data; subsequent 
incidence of recurrence and mortality was simulated using a de novo Markov model.  Health 
benefit was measured in quality adjusted life years (QALYs) and costs reported in 2015 
British pounds. Model parameters were derived from trial data and published literature. 
Sensitivity analyses were conducted to assess the impact of uncertainty and broader NHS & 
personal social services (PSS) costs on the results.  
Results: PET-CT management produced an average per-person lifetime cost saving of 
£1,485 and an additional 0.13 QALYs. At a £20,000 willingness-to-pay per additional QALY 
threshold there was a 75% probability that PET-CT was cost-effective, and the results 
remained cost-effective over the majority of sensitivity analyses. When adopting a broader 
NHS & PSS perspective, PET-CT management produced an average saving of £700 and had 
an 81% probability of being cost-effective.  
Conclusions: This analysis indicates that PET-CT guided management is cost-effective in 
the long-term and supports the case for wide scale adoption.  
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Introduction  
Chemo-radiotherapy has become a mainstay of primary treatment for many patients with 
squamous-cell carcinoma of the head and neck. However, for patients with advanced nodal 
disease (stage N2 or N3) there remains variation in subsequent treatment management. 
Evidence of persistent disease in nodes after neck dissection in up to 40% of patients, combined 
with some evidence of a survival advantage resulting from surgery, has led to many centres 
maintaining neck dissection as the preferred treatment strategy [1-3]. However, in the 30-45% 
of patients exhibiting complete response on imaging after chemo-radiotherapy, less than 10% 
go on to experience disease recurrence [4, 5]; combined with recent improvements in imaging 
technology, this has led to the sporadic adoption of image-guided treatment strategies in some 
countries as a means of sparing low-risk patients from the morbidity and expense of 
unnecessary surgery.   
A recent UK clinical trial (PET-Neck) was conducted to assess the clinical utility and cost-
effectiveness of a combined 18F-fluorodeoxyglucose (FDG) positron-emission tomography 
and computed tomography (PET-CT) guided management for patients with advanced 
squamous cell carcinoma [6]. The study found that, over the trial 2-year follow-up period, 
overall survival was similar among patients in the PET-CT arm compared to those who 
underwent planned neck dissection (84.9% vs. 81.5% respectively). In addition, mainly as a 
result of fewer operations (54 vs. 221), the intervention was associated with a 2-year cost-
saving of £1,492. Combined with a small increase (+0.08) in quality-adjusted life years 
(QALY), PET-CT guided management was found to be cost-effective over the 2-year trial 
horizon.   
Uncertainty remains over the long-term cost-effectiveness of image-guided management. 
Initial cost-savings associated with PET-CT (largely attributable to the lower procedural cost 
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compared to neck dissection; currently £649 vs. £3,548 respectively in the UK [7]) may not 
translate into long term cost savings if surgery is merely delayed or if the rate of late-stage 
recurrence events requiring more aggressive treatments is increased. Wide-scale adoption of 
new and potentially expensive technologies requires robust evidence on both long term clinical 
effectiveness and cost-effectiveness, and local decision makers need to have a clear idea of 
financial implications. Full consideration of the downstream cost consequences of PET-CT, as 
well as the impact on patient mortality and quality of life, therefore needs to be addressed.  
Here we report results of the PET-Neck study lifetime cost-effectiveness analysis, which, 
together with previously published clinical outcomes [6], provides vital evidence for the 
viability of a PET-CT guided management strategy for this patient group.   
Methods 
Clinical trial 
The PET-Neck study was a UK pragmatic multi-centre phase III randomised non-inferiority 
trial (ISRCTN 13735240). Full details of the trial have been previously published [6]. Briefly, 
between October 2007 and August 2012, 564 adult patients with head and neck (including 
oropharyngeal, laryngeal, oral, hypopharyngeal or occult) squamous cell carcinoma with nodal 
stage N2 or N3 and no distant metastasis (stage M0) disease were recruited across 43 UK 
National Health Service (NHS) hospitals. Patients were randomised 1:1 to receive either (a) 
standard care, consisting of planned neck dissection either before (within 4-weeks of 
randomisation) or after (within 4-8 weeks of chemo-radiotherapy completion) primary chemo-
radiotherapy treatment, or (b) PET-CT management, consisting of chemo-radiotherapy 
followed by PET-CT scan after 10-12 weeks, with neck dissection administered within 4 weeks 
of a positive or equivocal PET-CT scan. No surgery was undertaken if patients did not have 
evidence of residual disease. All patients received subsequent ongoing follow-up including 
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regular clinical examinations. The primary outcomes of the trial were overall survival and cost-
effectiveness, and all patients were followed up for a minimum of 2 years post randomisation. 
Requests for survival and recurrence status at the end of the trial provided additional follow-
up up to 5 years. Ethical approval for this trial was provided by the Oxfordshire Multi-Research 
Ethics Committee in May 2007 (Ref No: 07/Q1604/35). 
Health economic analysis 
The PET-Neck health economic evaluation consisted of two components: (i) a previously 
reported within trial (2-year) analysis [6]; and (ii) a lifetime analysis (the focus of this paper), 
in which the cost-effectiveness of PET-CT management versus planned neck dissection is 
assessed over a lifetime horizon using a modified Markov model.  
The primary analysis was conducted from an UK NHS secondary care perspective (i.e. 
including hospital costs only); sensitivity analyses were conducted including wider NHS and 
personal social services (PSS) costs. Patient health benefit was measured in quality adjusted 
life years (QALYs): a composite measure of patient health-related quality of life - ranging 
from perfect health (1) to death (0) - and patient life-years. Costs are reported in 2015 British 
pounds (£) and future cost and health outcomes (beyond one year) were discounted at an 
annual rate of 3.5% as per the National Institute of Health and Care Excellence (NICE) 
guidance [8]. All analyses were conducted in R (version 3.1.2) [9].  
Lifetime decision model  
A de novo decision analytical model was constructed to estimate cost-effectiveness over a 
lifetime horizon (truncated at 100 years). The model is split into two phases (see Figure 1: 
Simplified lifetime decision model structure). In the initial 6-month treatment phase, patients 
in the standard care arm (arm A) receive planned neck dissection (ND) either before or after 
chemo-radiotherapy (CRT), whilst patients in the PET-CT management arm (arm B) receive 
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chemo-radiotherapy followed by a PET-CT scan at 10-12 weeks post-chemo-radiotherapy 
which dictates whether or not patients go on to receive neck dissection. Costs and QALYs for 
the treatment period of the model were derived using individual participant data from the first 
6 months of the trial. After 6 months, a Markov model was used to capture the health and cost 
implications of disease recurrence, for which the trial provided limited data. 
Treatment period 
Over the initial 6-month treatment period, patient health-related quality of life was measured 
using patient responses to the EQ-5D-3L questionnaire (collected at baseline, 2 weeks post 
chemo-radiotherapy and at 3, 6, 12, and 24 months post-randomisation). Multiple imputation 
was used to impute missing EQ-5D values, and patient utility scores were assigned to each of 
the EQ-5D defined health states using standard UK tariffs [10]. QALYs were calculated by 
combining utility values with overall survival data, using the Kaplan-Meier method to 
account for loss to follow-up.  
Patients’ use of hospital resources (e.g. surgical procedures, radiotherapy, chemotherapy, 
severe adverse events, patient follow-up assessments and recurrence events) was determined 
using the trial case report forms. National unit costs (reported in online supplementary 
material, Table S1) were applied to each of the resource items and any costs reported in 2014 
prices were inflated to year 2015 using a consumer price index inflation value of 1.005 [7] 
[11-13]. Bootstrap analysis (i.e. data sampling with replacement) was conducted to assess the 
impact of sampling uncertainty around the 6-month cost and QALY results.  
Markov model 
Outcomes beyond the 6-month treatment period were simulated using a cohort Markov-
model. The model consisted of four health states: Disease Free (DF), Local Recurrence (LR), 
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Distant (or unresectable) Recurrence (DR), or Death. Patients could transition between each 
of the model health states over monthly model cycles.  
Model parameters were derived directly from trial data or from the literature using targeted 
searches where necessary (see Table 1: Markov model parameters). The proportion of 
patients beginning in each state of the model was taken directly from the trial data on overall 
survival and recurrences after 6 months. The cost and utility of the disease free state was 
based on the average monthly cost and utility values for patients who remained disease-free 
over the trial follow-up period (6-24 months), and the cost of initial treatment for recurrences 
was based on trial data on treatments administered upon recurrence. For patients who 
recovered from local recurrences, ongoing costs were assumed to be equal to those in the 
disease free state, whilst for patients remaining in the distant recurrence state an ongoing 
cancer supportive care cost was applied, derived from the literature [14]. Utilities for local 
and distant recurrence states were similarly taken from the literature [15]. Mortality within 
the disease free and local recurrence states were assumed equal to general population 
mortality (taken from Office of National Statistics [16]), multiplied by a factor of 20% 
derived from the literature [17]. Mortality within the distant recurrence state was determined 
by calibrating the model survival curve against the Kaplan Meier overall survival curve from 
the trial.  
A key parameter in the model concerns the rate of primary recurrence over time. In the base 
case analysis, recurrence data from the trial extended follow-up was used to directly inform 
recurrence rates up to year five, with subsequent recurrence assumed to drop to zero in both 
arms (since recurrence at 5 years was observed to be approaching zero in both arms of the 
trial; see online supplementary material, Figure S1). Uncertainty around the rate of recurrence 
was captured by simulating 10,000 bootstrap data samples from the trial Kaplan Meier 
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survival data. In addition, a sensitivity analysis was conducted to explore the impact of 
allowing recurrences beyond year 5 by fitting parametric survival curves to the within-trial 
Kaplan Meier recurrence survival plots (full details in online supplementary material; see 
Table S2 and S3, and Figures S2-S4). Subsequent recurrence rates (i.e. secondary recurrence 
onwards) were derived from the literature [18].  
Analysis 
Cost-effectiveness was determined using the Incremental Cost-Effectiveness Ratio (ICER), 
which represents the additional cost required to be spent on a new intervention in order to 
gain an additional unit of health (i.e. QALY). Treatments are considered cost-effective if the 
mean ICER falls below a given decision-makers willingness-to-pay per additional health unit; 
here we adopt NICE’s lower willingness-to-pay per additional QALY threshold of £20,000 
per QALY. An intervention that is more effective and less costly than standard care is 
considered dominant and in such cases the ICER is meaningless (as there is no trade-off 
between additional costs and health benefits to consider) and is therefore not reported.  
All primary analyses used probabilistic sensitivity analysis to capture the impact of joint 
parameter uncertainty on the results, based on 10,000 Monte-Carlo simulations. Model 
parameters were represented by appropriate probability distributions, with a different set of 
parameter values randomly selected within each model simulation to produce a distribution of 
10,000 cost and QALY results. A series of one-way sensitivity analyses (altering individual 
model parameters by +/- 25% of their base case mean value) were also conducted. 
A further sensitivity analysis was conducted adopting a broader NHS and PSS perspective. 
This analysis used data on patients’ use of secondary care outside of their enrolled hospital, 
as well as primary and community care, and was derived from patient reported resource-use 
forms used within the trial on a subset (n=42) of participants (full details in online 
12 
 
 
supplementary data; results presented in figures S5 and S6). Since this analysis relied on data 
from a small subset of patients it is considered as exploratory only.  
Results 
PET-CT guided management was associated with a per-patient lifetime NHS secondary care 
cost saving of £1,485 [$2,133] (95% CI: -2,815 to 159) and a health gain of 0.13 (95% CI: -
0.49 to 0.79) QALYs compared to planned neck dissection (see Table 2: lifetime cost-
effectiveness results and Figure 2: scatter plot)1. At a £20,000 [$28,736] per QALY threshold 
PET-CT was cost-saving 96% of the time, more effective than planned neck dissection 66% 
of the time, and the most cost-effective strategy 75% of the time.   
The level of uncertainty around the cost-effectiveness of PET-CT management over different 
willingness-to-pay per additional QALY thresholds is illustrated in the cost-effectiveness 
acceptability curve (CEAC) shown in Figure 3.2 The probability that the PET-CT 
management strategy is cost-effective remains above 67% up to a £150,000 [$215,517] per 
QALY threshold.  
Broadening the analysis to an NHS and PSS perspective resulted in substantial increases in 
the overall costs in both arms, with an average saving of £700 in favour of PET-CT, and an 
81% probability that PET-CT management is cost-effective at a £20,000 per QALY threshold 
(see Table 2).  Allowing secondary and subsequent recurrences to occur beyond 5 years in the 
model led to a slight reduction in the expected additional QALYs to +0.10 (95% CI:-0.56 to 
                                                          
1 Figure 2 shows the incremental cost and quality adjusted life year (QALY) results for PET-CT management 
versus standard care for each of the 10,000 model simulations (i.e. the scattered dots). The diagonal line 
represents a willingness-to-pay per additional QALY threshold of £20,000 per QALY. Points below this line are 
considered cost-effective; points above this line are not considered cost-effective. The triangle indicates the 
mean incremental cost and QALY result. 
2 Figure 3 shows the probability that PET-CT management is cost-effective versus standard care (i.e. the 
proportion of points lying under the willingness-to-pay per additional QALY threshold in figure 2) over 
alternative threshold values. 
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0.80), but PET-CT remained dominant with a 71% probability of being cost-effective (results 
presented in online supplementary material).    
One-way sensitivity analysis 
Results of the one-way sensitivity analysis are presented in Figure 4.3 The results are most 
sensitive to changes in relative rate of primary recurrences in each arm. 
Discussion  
In addition to verifying the effects on survival and recurrence rates, research into long-term 
health economic implications is critical in order to determine the overall value of treatment 
strategies by weighing up both cost and health outcomes at all points along the patient pathway. 
This evaluation provides the first confirmation that PET-CT guided management is likely to 
provide a cost-effective alternative to planned neck dissection within a randomised setting in 
the longer term, and from a UK healthcare perspective. This adds support to the previous body 
of studies in favour of adopting PET-CT into routine clinical practice.  
We found that, on average, PET-CT guided management is expected to produce long-term cost 
savings and improve patient outcomes, similar to results of the previously reported within-trial 
analysis [6]. The main difference is an increased level of uncertainty (with the probability that 
PET-CT management is cost-effective dropping from 99% to 75%), which is an expected 
consequence of any model attempting to extrapolate from short-term to long-term outcomes. 
The findings are also in line with previous economic evaluations undertaken in non-randomised 
studies: in a recent study Pryor et al. found that a similar PET-CT guided strategy was a safe 
                                                          
3 Figure 4 shows the change in the base case model results when changing individual model parameters by +/- 
25%. The cost-effectiveness of PET-CT management is presented in terms of the overall Incremental Net Health 
Benefit (INHB), which is a composite measure of incremental cost and quality adjusted life years (QALYs): 
additional costs are converted into lost QALYs by dividing by the willingness-to-pay per additional QALY 
threshold (£20,000), and this is subtracted from the additional QALYs associated with PET-CT management. 
INHB values above zero are considered to be cost-effective, whilst values below zero (indicated by the shaded 
region) are not considered to be cost-effective. Note: only parameters with the highest impact are shown.   
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and significantly less costly alternative strategy to planned surgery from an Australian health 
service perspective [19], and three studies have demonstrated cost-effectiveness from a United 
States health care perspective [20-22].  
The results remained cost-effective over a range of sensitivity analyses. The notable exception 
is when considering changes to the rate of primary recurrence. In the base case analysis, as a 
result of non-significantly different recurrence-free survival observed between treatment arms 
in the trial and zero primary recurrences assumed beyond five years, there was no resulting 
long-term negative consequences from averting surgery. Artificially raising the rate of 
recurrence in the intervention arm, however, has a predictably detrimental impact on the 
expected cost-effectiveness, with PET-CT management no longer being cost-effective when 
the rate of recurrence is increased by 25% in that arm.  
A key limitation of our analysis concerns the limited NHS secondary care perspective adopted 
in the base case analysis.  For patients with advanced nodal disease, it is highly probable that 
subsequent treatment management will take place in hospital, and we therefore expect this 
analysis to capture the key cost elements; it is preferable however that cost-effectiveness 
assessments should account for all resources which will be consumed as a result of 
implementing the new intervention. This restricted perspective was adopted as a result of a lack 
of sufficient data within the trial upon which to derive full NHS or societal costs and is a 
frequent problem encountered in cancer trials. We conducted a sensitivity analysis looking at 
potential impact on broader NHS costs using data on a subset of patients in whom additional 
resource use data was collected. It is encouraging that these exploratory results support the 
main findings; however these results need to be interpreted with caution due to the small sample 
size.  
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Further limitations of the analysis relate to the quality of evidence from the literature used to 
inform several of the model parameters. As with any model, uncertainty is introduced when 
using disparate sources to inform model inputs, and finding quality sources to inform post-
recurrence outcomes is a particular issue in such analyses due to the difficulty of capturing 
such data. We conducted a range of sensitivity analyses in order to identify any key uncertain 
parameters. As discussed, the results were found to be largely robust.  
In conclusion, our study indicates that the use of PET-CT guided management for patients with 
advanced head and neck cancer after primary chemo-radiotherapy reduces lifetime costs and 
improves patient health outcomes. Whilst our analysis focuses on the UK, the results are likely 
to be relevant to international healthcare settings where clinical pathways and procedural costs 
are similar.  
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Tables 
Table 1. Markov model parameters 
Parameter Mean Standard Deviation Distribution Source 
Global parameters 
Discount rate 0.035 - Fixed NICE guidance [8] 
Start Age 57 - Fixed 
PET-Neck trial data [this study] 
Proportion Male 0.82 - Fixed 
Markov model health state starting distributions (end of trial 6 month treatment period) 
Planned ND: Recurrence 0.06 0.015 Beta 
PET-Neck trial data [this study] 
Planned ND:  Proportion of 
recurrences local vs. distant 0.35 0.069 Beta 
Planned ND: Dead 0.03 0.01 Beta 
PET-CT: Recurrence 0.05 0.013 Beta 
PET-CT: Proportion of 
recurrences local vs. distant 0.41 0.066 Beta 
PET-CT: Dead 0.02 0.008 Beta 
Monthly health state costs   
DF £71 £106 Gamma PET-Neck trial data [this study] 
on DF  (n=439) and LR (n=39) 
patients LR initial treatment  £4,080 £4,386 Gamma 
DF after LR £71 £106 Gamma Assumed equivalent to DF cost 
DR initial treatment £3,726 £3,205 Gamma PET-Neck trial data [this study] on DR patients (n=63) 
DR ongoing care £140 £32 Gamma 
Hall et al. 2014. [14] 
Terminal-month cost £1,051 £115 Gamma 
Health state utilities 
DF 0.70 0.03 Beta PET-Neck trial data [this study]  
LR decrement -0.11 0.12 Beta Almeida et al. 2008  [15] 
DF after LR 0.70 0.03 Beta Assumed equivalent to DF utility 
DR decrement -0.47 0.2 Beta Almeida et al. 2008 [15] 
Dead 0 - Fixed - 
Transition probabilities/ effects  
Recurrence over first 5 years 
10,000 bootstrap simulations of 
Kaplan Meier recurrence-free 
survival curves, in each arm 
PET-Neck trial data [this study] 
Planned ND: proportion of 
recurrences local vs. distant  0.35 0.069 Beta Assumed equivalent to rate 
observed within PET-Neck trial PET-CT: proportion of 
recurrences local vs. distant  0.41 0.066 Beta 
Probability of LR from DF after 
LR  0.02 0.002 Beta 
Matoscevic et al. 2014  [18] 
Probability of DR from LR/ DF 
after LR 0.02 0.003 Beta 
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Baseline mortality in DF/ LR Life Table - Fixed 
Office for National Statistics, 
2013 age- and sex- standardized 
rates [16] 
Excess mortality factor for DF 
and LR  1.2 - Fixed Van der Schroeff et al. 2010 [17] 
DR mortality 0.3 0.3 Beta 
Calibration of model survival 
curve against PET-Neck trial 
survival data 
ND= Neck Dissection; PET-CT= positron-emission tomography and computed tomography; DF= Disease Free; LR= Local Recurrence; DR= 
Distant Recurrence. 
 
 
Table 2. Lifetime cost-effectiveness results 
Strategy 
Total Cost  Total QALY  Incremental      Cost  
Incremental 
QALY  ICER 
Probability      
cost-
effective (95% CI) (95% CI) (95% CI) (95% CI) 
NHS secondary care perspective (base case) 
Planned ND 
£24,074 9.01 
- - - - 
(12,947 – 63,200)  (7.87 – 10.46) 
PET-CT 
£22,589 9.14 -£1,485 0.13 
Dominant 75% 
(11,319 – 62,155)  (8.05 – 10.55) (-2,815 – 159)  (-0.49 – 0.79) 
NHS & PSS perspective (sensitivity analysis) 
Planned ND 
£99,898 9.01 
- - - - 
(68,360 – 139,654) (7.87 – 10.46) 
PET-CT 
£99,198 9.13 -£700 0.13 
Dominant  81% 
(67,304 – 139,049) (8.05 – 10.54) (-6,190 – 5,362) (-0.49 – 0.79) 
CI = confidence interval; QALY= quality adjusted life year; ICER= incremental cost-effectiveness ratio; ND= neck dissection; PET-CT= 
positron-emission tomography and computed tomography; NHS= National Health Service; Dominant= more effective and less costly 
than standard care (ICER not reported in these cases). 
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Figures 
Figure 1. Simplified lifetime decision model structure 
 
 
Figure 2. Scatter plot of base case lifetime cost-effectiveness results using an NHS 
secondary care perspective 
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Figure 3. Cost-effectiveness acceptability curve (CEAC) for the base case lifetime cost-
effectiveness results using an NHS secondary care perspective 
 
 
Figure 4. One-way sensitivity analyses for lifetime cost-effectiveness results using an 
NHS secondary care perspective 
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1. Unit Costs applied to trial resource use data 
Units costs applied to the trial resource use data in the economic analysis are presented in 
Table S1.  Note: prices are reported as given in the original source i.e. non-inflated.  
Table S1. Unit costs applied to trial resource use data 
 
Resource Item Unit 
cost Source Details/ assumptions 
Secondary care costs (relating to trial case report form items) 
Inpatient “hotel cost” (per 
night cost) £200 
East and North 
Hertfordshire NHS 
Trust Performance 
Report. [23] 
 
Oncology assessment £181 
NHS Ref costs 
2013/14. [7]  
 
Medical oncology first face-to-face 
attendance.  
Cardiology assessment £160 Cardiology first face-to-face attendance.  
Respiratory assessment £186 Respiratory Medicine first face-to-face attendance.  
Other assessment £196 General Medicine first face-to-face attendance.   
Dental assessment  £126 Dental Medicine first face-to-face attendance.  
Nasopharyngoscopy 
 £114 
Diagnostic Nasopharyngoscopy, 19 
years and over.  
Fine needle aspiration  £164 Minor Maxillofacial Procedures.  
Surgery assessment £150 General surgery first face-to-face attendance.  
CT scan  £147 Computerised Tomography Scan, more than three areas.  
PET-CT Scan £649 Nuclear Medicine, Category 8 (PET-CT). 
MRI Scan  £145 
Magnetic Resonance Imaging Scan, 
one area, post contrast only, 19 years 
and over.  
X-ray  £40 
Personal 
communication with 
Leeds Teaching 
Hospitals Trust.  
 
Ultrasound £76 NHS Ref costs 
2013/14. [7]  
Ultrasound Mobile Scan or 
Intraoperative Procedures, less than 20 
minutes.  
Other radiography 
assessment £88 
Clinical Oncology (Previously 
Radiotherapy) first attendance.  
Nurse assessment  £100 
PSSRU 2014. [12] 
Assume an assessment is equivalent to 
1 hour of contact time.  
Palliative care assessment  £97  
Social other £37 Assume equivalent to speech/diet assessment.  
Speech assessment  £37 Assume an assessment is equivalent to 1 hour of contact time. 
Dietician assessment  £37 As above.  
Rehabilitation assessment  £36 Assume equivalent to 1 hour of occupational therapist contact time.  
Psychology assessment  £138 Assume hospital assessment cost equivalent to community visit cost.  
Counselling assessment  £50 As above.  
Pegswab  £7 
NHS Ref costs 
2013/14. [7] 
Directly Accessed - Pathology 
Services. Microbiology.  
Bloods- haematology £3 Directly Accessed - Pathology Services. Haematology  
Bloods- biochemistry £1 Directly Accessed - Pathology Services. Clinical Biochemistry.   
Bloods- microbiology £7 Directly Accessed - Pathology Services. Microbiology.  
Bloods- other £8 Directly Accessed - Pathology Services. Other.  
Secondary care costs (relating to trial patient-reported items) 
Short stay (≤2 days) 
inpatient cost £611 p111 2014 PSSRU. 
[12] 
 
Long stay (>2 days) 
inpatient cost £2716  
Hospital day centre £119 NHS Ref Costs 2013/14. [7] 
Inpatient Specialist Palliative Care, 
Same Day, 19 years and over.  
Outpatient visit £109 2014 PSSRU. [12]  
Accident and Emergency 
visit £135 
NHS Ref Costs 
2013/14. [7] Total Outpatient Attendances.  
Nursing/ convalescent home £82 2014 PSSRU. [12] 
Assume cost for 1 day and night equals 
the reported private sector nursing 
home cost per week / 7.  
Primary and community care service costs (relating to trial patient-reported items) 
GP surgery visit  
(phone call) 
£46 
(28) 
2014 PSSRU. [12] 
 
GP home visit £67 Assume equal to reported cost for 17 min surgery visit.     
District nurse home visit  
(phone call) 
£66 
(11) 
Assume each visit equal to 1 hour 
contact time and a call is equivalent to 
10 mins of contact time.  
Social worker visit         
(phone call) 
£79 
(13) As above.  
Physiotherapist visit      
(phone call) £36 (6)  As above.  
Occupational therapist visit 
(phone call) £36 (6)  As above. 
Counsellor visit              
(phone call) £50 (8) As above.  
Home help service £24 (4) 
Assume a visit is equal to 1 hr of 
weekday contact and a call is 
equivalent to 10 mins of this time.   
Psychiatrist  £138 
Assume a visit is equal to 1 hr contact 
time and a call is equivalent to 10 mins 
of contact time. 
Day centre £24 Assume equivalent to home help service visit.  
Chemotherapy drug costs 
5FU £3.47 
eMIT 2015. [11] 
5g/100ml vial, 5%, size 1.  
Cisplatin £16.69 100mg/100ml vial.  
Carboplatin £28.89 600mg/60ml vial.   
  
 
Cetuximab £890.50 5mg/ml, 100ml vial.  
Docetaxel £29.78 160mg/8ml vial.  
Delivery cost £328 NHS Ref costs 2013/14. [7] 
Deliver subsequent elements of a 
chemotherapy cycle.  
Radiotherapy costs 
Radiotherapy delivery £149 NHS Ref costs 
2013/14. [7] 
Deliver a fraction of complex treatment 
on a megavoltage machine.  
Radiotherapy planning visit £1587 Prep for Intensity Modulated Radiation Therapy, with Tech Support.  
Surgery costs 
Node dissection  £3548 
NHS Ref costs 
2013/14. [7] 
Elective inpatient. Intermediate 
Maxillofacial Procedures.  
Salvage surgery £7722 
Elective inpatient. Major Maxillofacial 
Procedures, 19 years and over, with 
CC Score 1+.  
Follow-up visit assessment costs   
Anaesthetic examination  £85 
NHS Ref costs 
2013/14. [7] 
Anaesthetics: Diagnostic, 
Laryngoscopy or Pharyngoscopy, 19 
years and over.  
Biopsy £164 Maxillo-Facial Surgery: Minor Maxillofacial Procedures.  
Clinical exam  £109 
Maxillo-Facial Surgery: Diagnostic, 
Laryngoscopy or Pharyngoscopy, 19 
years and over.  
Recurrence treatment costs 
Brachytherapy £2,393 
NHS Ref costs 
2013/14. [7] 
 
1 x Preparation for interstitial 
brachytherapy (£1,196). 1 x Deliver a 
Fraction of Intraluminal Brachytherapy 
(£1,197).  
Chemotherapy course £4,753  
6 x Procure chemotherapy drugs for 
regimens in Band 2 (£323).  1 x 
Deliver more complex Parenteral 
Chemotherapy at first attendance 
(£317). 5 x Deliver subsequent 
elements of a chemotherapy cycle 
(£328). 6 x Medical Oncology Follow-
up  
Radiotherapy course £1,744 Assumes 1 radiotherapy planning visit and 1 delivery.  
Annual supportive care cost 
post distant recurrence £1,682 
P.Hall et al. 2014. [14] 
 
Terminal month palliative 
care cost post distant 
recurrence 
£1,051  
Resection/ Free Flap 
Reconstruction £7722 
NHS Ref costs 
2013/14. [7] 
Elective inpatient. Major Maxillofacial 
Procedures, 19 years and over, with 
CC Score 1+.  
CC= Currency code; SC= Service code  
2. PET-Neck within-trial time to recurrence plots 
Time to recurrence by treatment arm within the extended 5-year PET-Neck trial follow-up 
period is shown in Figure S1. For Kaplan-Meier analysis of recurrence, the time of recurrence 
was taken as the time from completion of radiotherapy to reported recurrence or to cancer 
death if there was no reported recurrence.   
Figure S1. Time to recurrence by treatment arm over 5-year PET-Neck trial follow-up 
period  
 
 
 
 
 
 
 
 
 
3. Sensitivity analysis methods and results: primary recurrence beyond year five 
 
Methods 
In the base case analysis no recurrence events were assumed to occur beyond year five in the 
model. A sensitivity analysis was conducted assuming recurrences could occur beyond year 
five by fitting parametric survival curves to the within-trial recurrence free survival Kaplan 
Meier plots. Long term recurrence probabilities for the planned neck dissection arm were 
estimated using a Gompertz parametric survival curve fitted to the trial baseline Kaplan 
Meier data; a hazard ratio (HR) was then applied to this curve in order to derive survival 
within the PET-CT management arm (using the HR observed across the trial follow-up 
period= 1.008). 
The Gompertz distribution was identified as the best fitting curve to estimate long term 
recurrence events (compared to the Exponential, Weibull, Gamma and Lognormal 
distributions), based on an analysis of AIC and BIC criteria (see Table S2; better fitting 
curves are indicated by lower AIC and BIC values) and a visual inspection of the curve fits 
(see Figure S2: Plot of parametric survival curves (using Gompertz and Log-normal model 
specifications) against trial data on patient recurrence free survival).1   
 
 
 
 
 
 
 
 
 
                                                          
1 Note: lognormal and Gompertz specifications are shown here as these were the two models 
identified as having the best fit via an analysis of AIC and BIC criteria. The Gompertz curve was used 
in the sensitivity analysis as this had the best overall fit when taking into account AIC and BIC 
criteria and a visual inspection of the goodness of fit.  
Table S2. AIC and BIC criteria to estimate the goodness of fit of alternative parametric 
survival curve model specifications for the estimation of long term recurrences 
 
Model specification AIC BIC  
Planned ND arm 
Exponential  679.50 683.14 
Gamma 674.96 682.96 
Weibull 673.83 681.11 
Lognormal  665.86 673.14 
Gompertz 659.03 666.31 
PET-CT surveillance arm  
Exponential  734.08 737.72 
Gamma 735.58 742.86 
Weibull 735.16 742.44 
Gompertz 727.89 735.17 
Lognormal  726.19 733.48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Plot of parametric survival curves (using Gompertz and Log-normal model 
specifications) against PET-Neck trial data on patient recurrence free survival 
 
 
Results 
Results of the sensitivity analysis allowing primary recurrences beyond year five are 
presented in Table S3 (results table), Figure S3 (scatter plot) and Figure S4 (cost-
effectiveness acceptability curve). 2,3   
Table S3.  Lifetime cost-effectiveness results for sensitivity analysis allowing 
recurrences beyond year 5 (NHS & PSS perspective) 
 
Strategy 
Total Cost  Total QALY  Incremental      Cost  
Incremental 
QALY  ICER 
Probability      
cost-
effective (95% CI) (95% CI) (95% CI) (95% CI) 
Planned ND £24,313 (13,149 – 63,642) 
8.76 
(7.60 – 10.32) - - - 
 
PET-CT £22,841 
(11,492 – 62,359) 
8.86 
(7.73 – 10.40) 
-£1,472 
(-2,934 – 381) 
0.10 
(-0.56 – 0.80) Dominant 71% 
CI = confidence interval; QALY= quality adjusted life year; ICER= incremental cost-effectiveness ratio; ND= neck dissection; PET-CT= 
positron-emission tomography and computed tomography; Dominant= more effective and less costly than standard care (ICER not 
reported in these cases). 
 
 
 
 
 
 
 
 
 
 
                                                          
2 Figure S3 shows the incremental cost and quality adjusted life year (QALY) results for PET-CT 
management versus standard care for each of the 10,000 model simulations (i.e. the scattered dots). 
The diagonal line represents a willingness-to-pay per additional QALY threshold of £20,000 per 
QALY. All points below this threshold line are considered cost-effective; points above this line are 
not considered cost-effective. The triangle indicates the mean incremental cost and QALY result. 
3 Figure S4 shows the probability that PET-CT management is cost-effective versus standard care (i.e. 
the proportion of points lying under the willingness-to-pay per additional QALY threshold) over 
alternative threshold values. 
 
Figure S3. Scatter plot of lifetime cost-effectiveness results for sensitivity analysis 
allowing recurrence beyond year 5 
 
 
Figure S4. Cost-effectiveness acceptability curve (CEAC) for sensitivity analysis 
allowing recurrence beyond year 5 
 
 
4. Sensitivity analysis: NHS & PSS perspective 
 
Methods 
In the base case analysis, costs were calculated using data from the trial case report forms 
which provided information on a range of secondary care resource usage for the total trial 
population (n=564). Additional data on primary and community care resource usage, as well 
as additional secondary care resource usage (outside of the enrolled oncology department), 
was collected for a subgroup of the trial population (n=42) enrolled at the two main recruiting 
centres. These patients were asked to recall their use of NHS and PSS services over the past 3 
months (or since completion of the last form where appropriate) at baseline, during treatment 
(2 weeks post CRT), and at 3, 6, 12 and 24 months post randomisation. A sensitivity analysis 
was conducted to assess the potential impact of including this additional cost data, by 
imputing the mean reported values for the additional resource use items collected in the 
patient-reported forms to the total trial population. Mean values were calculated using a 
complete case analysis of the patient- reported data. Due to the small sample size it was 
deemed inappropriate to attempt to conduct multiple imputation for missing data.  
Within the patient-reported questionnaires, patients were asked to report any additional visits 
to hospital (inpatient, day centre, outpatient, A&E or nursing home visits), not including 
visits to their enrolled oncology department; this was in order to capture additional secondary 
care resource usage not already captured in the case report forms routinely completed at the 
patient’s enrolled oncology department. However, where additional hospital visits were 
reported, patients were asked to give the name of the hospital they visited, and a significant 
number of patients identified the hospital as the same as that to which they were enrolled in 
the trial. In such cases it was assumed that this data would already have been captured in the 
trial case report forms and these events were therefore excluded from the analysis.  
Results 
Results of the sensitivity analysis using an NHS and PSS perspective over a lifetime horizon 
are presented in Figure S5 (scatter plot) and Figure S6 (cost-effectiveness acceptability 
curve). Note: the results table for this analysis is reported in Table 2 in the main article text.4,5  
Figure S5. Scatter plot of lifetime cost-effectiveness results using an NHS and PSS 
perspective  
 
 
 
 
 
 
                                                          
4 Figure S5 shows the incremental cost and quality adjusted life year (QALY) results for PET-CT 
management versus standard care for each of the 10,000 model simulations (i.e. the scattered dots). 
The diagonal line represents a willingness-to-pay per additional QALY threshold of £20,000 per 
QALY. All points below this threshold line are considered cost-effective; points above this line are 
not considered cost-effective. The triangle indicates the mean incremental cost and QALY result. 
5 Figure S6 shows the probability that PET-CT management is cost-effective versus standard care (i.e. 
the proportion of points lying under the willingness-to-pay per additional QALY threshold) over 
alternative threshold values. 
 
Figure S6. Cost-effectiveness acceptability curve (CEAC) for the lifetime cost-
effectiveness results using an NHS and PSS perspective  
 
 
 
 
 
 
 
